Navigation Links
BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015

SAN DIEGO, Jan. 15 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) announced today the signing of two lease extensions in Cambridge, Massachusetts with Vertex Pharmaceuticals Incorporated, totaling over 292,000 square feet at BioMed's 40 Erie Street (also known as Vertex's Corporate Headquarters at 130 Waverly Street) and 200 Sidney Street properties. Both leases now extend through December 31, 2015. In total, Vertex leases approximately 685,000 square feet at five BioMed properties, including approximately 604,000 total square feet in Cambridge and 81,000 square feet in San Diego.

This early renewal successfully addresses BioMed's largest, single tenant lease expiration in the next five years. BioMed's proactive approach to leasing and renewals has resulted in less than 3% of annualized based rents expiring in 2009 and less than 5% of annualized base rents expiring in 2010. In aggregate across its portfolio, BioMed's weighted average remaining lease term is approximately nine years.

"BioMed remains focused on being the leading provider of real estate to the life science industry, and these lease renewals demonstrate our strong relationship with Vertex and their ongoing commitment to our properties in both the Cambridge and San Diego core biotech markets," said Alan D. Gold, Chairman and Chief Executive Officer of BioMed Realty Trust. "We look forward to supporting Vertex as their company advances in the years ahead."

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 69 properties, representing 112 buildings with approximately 10.4 million rentable square feet, including approximately 1.4 million square feet of development in progress. The company also owns undeveloped land parcels adjacent to existing properties that it estimates can support up to 1.4 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at

About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and cystic fibrosis. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.

Lexiva is a registered trademark of the GlaxoSmithKline group of companies.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE BioMed Realty Trust, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Bavarian Nordics Case Against Oxford BioMedica
2. BioLife Solutions Joins Prestigious Biomedical Excellence for Safer Transfusion Collaborative
3. BioMed Realty Trust Declares Fourth Quarter 2008 Common Stock and Preferred Stock Dividends
4. BioMed Realty Trust Promotes Kent Griffin to President
5. Alfred Mann Foundation for Biomedical Engineering Launches New Web Site Designed to Help University Researchers Bring Biomedical Advances to Market
6. BioFlorida Selects Collexis as the Primary Professional Network for its 200 Member Companies and Organizations
7. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
8. SpineSmith Partners Collaborates with University of Texas Biomedical Engineering Students to Develop Innovative Products
9. Ohio Becoming Global Hub for Biomedical Research and Commercialization
10. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
11. Environmental Tectonics Corporation Announces Staff Addition to Its BioMedical Systems Division
Post Your Comments:
(Date:10/8/2015)... , October 8, 2015 ... Global Biologics and Biosimilars industry . ... "Global Biologics and Biosimilars Industry 2015 Deep Market ... Forecast" is a professional and depth research report ... ) , --> ...
(Date:10/8/2015)... -- Today the Wyss Institute for Biologically Inspired Engineering at ... Opsonix Inc. The announcement follows a worldwide ... Development (OTD) and Opsonix Inc. enabling the company ... --> --> ... year in the U.S. — more than prostate cancer, ...
(Date:10/7/2015)... October 8, 2015 ... biotechnology accounts for largest bioinformatics market share ... drug discovery and development process says this ... . --> ... basis of applications, the bioinformatics market is ...
(Date:10/7/2015)...  ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV ) ("ContraVir" ... development and commercialization of targeted antiviral therapies, today announced ... shares of its common stock and warrants to purchase ... at a fixed combined price to the public of ... be issued separately.  The warrants will be exercisable for ...
Breaking Biology Technology:
... /PRNewswire-Asia/ -- Global biomedical sciences companies,invested more than ... This rides on,Singapore,s strong scientific fundamentals, with biomedical ... The continued confidence in ... companies look to the fast growing Asian,market to ...
... Hai Kang Life Corporation Limited (HKLife) announces further ... EFADchip technology at the ... Biotechnology held in Atlanta, through 18-21 May 2009. ... gathering for the biotechnology industry and attracts the ...
... May 15, 2009 If one University of Houston professor ... CDs and DVDs will one day soon be put to ... and iPhones. , Thanks to a pair of ... of physics at UH, and his research team have demonstrated ...
Cached Biology Technology:
(Date:9/28/2015)... , Sept. 28, 2015 ... today that its expedited traveler service is ... platform transforms travel, bringing a frictionless experience, ... members. "CLEAR offers our travelers ... customer service," said Jim Smith , ...
(Date:9/28/2015)... 28, 2015 The global ... USD 12.03 billion by 2020, growing at a CAGR ... as Backside Illumination (BSI) technique to improve picture quality ... period.      (Logo: , ... to reduce loss and, thus, reduce the noise interference ...
(Date:9/28/2015)... , Sept. 28, 2015 Synaptics Inc. ... interface solutions, today announced that Lenovo has selected Synaptics ... sensor, FS4202, for its latest smartphone, the Vibe P1. ... access to unlock the device and provide swift access ... The feature-rich Natural ID FS4202 sensor solution utilizes ...
Breaking Biology News(10 mins):
... Safety System Equip Officers with Access to Mobile ... 6 BIO-key International, Inc. (OTC ... identification and wireless public safety solutions and its ... of Public Safety Software, announced nine recent mobile ...
... Johns Hopkins has convinced an international group of colleagues ... and instead begin a 7,000-hour slog through a compendium ... and analyze the molecules that might herald the furtive ... available for the exhaustive and expensive testing that needs ...
... 2009) Cell Press, an imprint of Elsevier, announced today ... Current Biology and The American Journal of ... (SLA) Top 100 Journals in Biology and Medicine of the ... the 680-plus members of the SLA,s Biomedical and Life Sciences ...
Cached Biology News: